Excellent outcome of Minimal residual disease-defined low-risk patients is sustained with more than 10 years follow-up: Results of UK paediatric acute lymphoblastic leUKaemia trials 1997-2003

Archives of Disease in Childhood

Volumn 101, Issue 5, 2016, Pages 449-454

  Bartram, Jack ^a   Wade, Rachel ^b   Vora, Ajay ^c   Hancock, Jeremy ^d   Mitchell, Chris ^e   Kinsey, Sally ^f   Steward, Colin ^g   Moppett, John ^g   Goulden, Nick ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^d SOUTHMEAD HOSPITAL   (United Kingdom)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^f ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^g Royal Hospital for Children   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; DEXAMETHASONE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; TIOGUANINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CHILD; CHILD SAFETY; CHILDHOOD LEUKEMIA; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LONG TERM SURVIVAL; LOW RISK PATIENT; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; SHORT TERM SURVIVAL; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; ADOLESCENT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GREAT BRITAIN; INFANT; MORTALITY; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; INFANT; MALE; NEOPLASM, RESIDUAL; PILOT PROJECTS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84959101777     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2015-309617     Document Type: Article

References (32)

1. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010;2010:7-12.
2. Campana D. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009;23:1083-98, vii.
3. Yeoh AE, Ariffin H, Chai EL, et al. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. J Clin Oncol 2012;30:2384-92.
4. Campana D. Minimal residual disease monitoring in childhood acute lymphoblastic leukemia. Curr Opin Hematol 2012;19:313-18.
5. Vora A, Goulden N, Wade R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol 2013;14:199-209.
6. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010;115:3206-14.
7. Yamaji K, Okamoto T, Yokota S, et al. Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group. Pediatr Blood Cancer 2010;55:1287-95.
8. Chessells JM, Richards SM, Bailey CC, et al. Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials. Br J Haematol 1995;89:364-72.
9. Mitchell CD, Richards SM, Kinsey SE, et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005;129:734-45.
10. Mitchell C, Richards S, Harrison CJ, et al. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001. Leukemia 2010;24:406-18.
11. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003;101:3809-17.
12. Eden OB, Harrison G, Richards S, et al. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party. Leukemia 2000;14:2307-20.
13. Vora A, Mitchell CD, Lennard L, et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 2006;368:1339-48.
14. Verhagen OJ, Wijkhuijs AJ, van der Sluijs-Gelling AJ, et al. Suitable DNA isolation method for the detection of minimal residual disease by PCR techniques. Leukemia 1999;13:1298-9.
15. Goulden NJ, Knechtli CJ, Garland RJ, et al. Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia. Br J Haematol 1998;100:235-44.
16. Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 1998;12:2006-14.
17. van der Velden VH, Cazzaniga G, Schrauder A, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007;21:604-11.
18. Vora AJ, Richards S, Hancock J, et al. Variables Affecting Kinetics of Minimal Residual Disease Clearance in Children with Lymphoblastic Leukaemia; Results of the United Kingdom Medical Research Council (UK MRC) Protocols ALL97, ALL97/99 and ALL2003. ASH Annu Meeting Abstr 2005;106:86.
19. Mitchell C, Payne J, Wade R, et al. The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99. Br J Haematol 2009;146:424-36.
20. Pui CH, Pei D, Campana D, et al. A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia 2014;28:2336-43Z.
21. Panzer-Grümayer ER, Schneider M, Panzer S, et al. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 2000;95:790-4.
22. Sutton R, Venn NC, Tolisano J, et al. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. Br J Haematol 2009;146:292-9.
23. zur Stadt U, Harms DO, Schluter S, et al. MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen. Leukemia 2001;15:283-5.
24. van Dongen JJ, Seriu T, Panzer-Grümayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998;352:1731-8.
25. Nyvold C, Madsen HO, Ryder LP, et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 2002;99:1253-8.
26. Metzker ML. Sequencing technologies-the next generation. Nat Rev Genet 2010;11:31-46.
27. Nekrutenko A, Taylor J. Next-generation sequencing data interpretation: enhancing reproducibility and accessibility. Nat Rev Genet 2012;13:667-72.
28. Izraeli S. Application of genomics for risk stratification of childhood acute lymphoblastic leukaemia: from bench to bedside? Br J Haematol 2010;151:119-31.
29. van Dongen JJ, van der Velden VH, Bruggemann M, et al. Minimal residual disease (MRD) diagnostics in acute lymphoblastic leukemia (ALL): need for sensitive, fast and standardized technologies. Blood 2015;125:3996-4009.
30. Irving J, Jesson J, Virgo P, et al. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting. Haematologica 2009;94:870-4.
31. Volejnikova J, Mejstrikova E, Valova T, et al. Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis. Haematologica 2011;96:1815-21.
32. Denys B, van der Sluijs-Gelling AJ, Homburg C, et al. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 2013;27:635-41.